The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascu...

Descripción completa

Detalles Bibliográficos
Autores principales: Atmowihardjo, Leila, Schippers, Job R., Bartelink, Imke H., Bet, Pierre M., van Rein, Nienke, Purdy, Keith, Cavalla, David, Comberiati, Valérie, McElroy, Andrew, Snape, Sue D., Bogaard, Harm Jan, Heunks, Leo, Juffermans, Nicole, Schultz, Marcus, Tuinman, Pieter R., Bos, Lieuwe D. J., Aman, Jurjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848942/
https://www.ncbi.nlm.nih.gov/pubmed/35172891
http://dx.doi.org/10.1186/s13063-022-06055-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848942/
https://www.ncbi.nlm.nih.gov/pubmed/35172891
http://dx.doi.org/10.1186/s13063-022-06055-9

Ejemplares similares